Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Average (2016 - 2025)

Historic Equity Average for Myriad Genetics (MYGN) over the last 15 years, with Q3 2025 value amounting to $380.4 million.

  • Myriad Genetics' Equity Average fell 4831.54% to $380.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $380.4 million, marking a year-over-year decrease of 4831.54%. This contributed to the annual value of $742.2 million for FY2024, which is 1106.65% down from last year.
  • Latest data reveals that Myriad Genetics reported Equity Average of $380.4 million as of Q3 2025, which was down 4831.54% from $546.5 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Equity Average peaked at $968.2 million during Q4 2021, and registered a low of $380.4 million during Q3 2025.
  • Moreover, its 5-year median value for Equity Average was $785.2 million (2023), whereas its average is $795.0 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 920.74% in 2022, then tumbled by 4831.54% in 2025.
  • Myriad Genetics' Equity Average (Quarter) stood at $968.2 million in 2021, then decreased by 6.92% to $901.2 million in 2022, then fell by 18.63% to $733.3 million in 2023, then decreased by 2.3% to $716.4 million in 2024, then plummeted by 46.89% to $380.4 million in 2025.
  • Its Equity Average was $380.4 million in Q3 2025, compared to $546.5 million in Q2 2025 and $703.0 million in Q1 2025.